Spruce Biosciences, Inc. Operating Lease Cost
Spruce Biosciences, Inc. (SPRB) reported Operating Lease Cost of $337.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-09
- Spruce Biosciences, Inc. operating lease, cost for the quarter ending 2022-12-31 was $65.00K, a 53.90% decline year-over-year.
- Spruce Biosciences, Inc. operating lease, cost for the quarter ending 2022-09-30 was $100.00K, a 0.00% change year-over-year.
- Spruce Biosciences, Inc. operating lease, cost for the quarter ending 2022-06-30 was $100.00K, a 0.00% change year-over-year.
- Spruce Biosciences, Inc. operating lease, cost for the quarter ending 2022-03-31 was $100.00K, a 0.00% change year-over-year.
- Spruce Biosciences, Inc. operating lease, cost for fiscal 2025 was $337.00K, a 0.30% increase from fiscal 2024.
- Spruce Biosciences, Inc. operating lease, cost for fiscal 2024 was $336.00K, a 0.30% decline from fiscal 2023.
- Spruce Biosciences, Inc. operating lease, cost for fiscal 2023 was $337.00K, a 27.53% decline from fiscal 2022.
- Spruce Biosciences, Inc. operating lease, cost for fiscal 2022 was $465.00K, a 5.44% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month | Operating Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | $337.00K 10-K · filed 2026-03-09 | |||||
| 2024-12-31 | $336.00K 10-K · filed 2026-03-09 | |||||
| 2023-12-31 | $337.00K 10-K · filed 2025-04-15 | |||||
| 2022-12-31 | $65.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $165.00K derived: sum of 2 quarters · filed 2024-03-18 | $265.00K derived: sum of 3 quarters · filed 2024-03-18 | $465.00K 10-K · filed 2024-03-18 | ||
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-10 | $200.00K derived: sum of 2 quarters · filed 2022-11-10 | $400.00K 10-Q · filed 2022-11-10 | $441.00K derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2022-06-30 | $100.00K 10-Q · filed 2022-08-10 | $200.00K 10-Q · filed 2022-08-10 | $341.00K derived: sum of 3 quarters · filed 2023-03-16 | $441.00K derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2022-03-31 | $100.00K 10-Q · filed 2022-05-11 | $241.00K derived: sum of 2 quarters · filed 2023-03-16 | $341.00K derived: sum of 3 quarters · filed 2023-03-16 | $441.00K derived: sum of 4 quarters · filed 2023-03-16 | ||
| 2021-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $241.00K derived: sum of 2 quarters · filed 2023-03-16 | $341.00K derived: sum of 3 quarters · filed 2023-03-16 | $441.00K 10-K · filed 2023-03-16 | $400.00K 10-K · filed 2022-03-14 | |
| 2021-09-30 | $100.00K 10-Q · filed 2022-11-10 | $200.00K derived: sum of 2 quarters · filed 2022-11-10 | $300.00K 10-Q · filed 2022-11-10 | $363.00K derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $100.00K 10-Q · filed 2022-08-10 | $200.00K 10-Q · filed 2022-08-10 | $263.00K derived: sum of 3 quarters · filed 2022-08-10 | $300.00K derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $100.00K 10-Q · filed 2022-05-11 | $110.00K 10-Q · filed 2021-05-12 | $163.00K derived: sum of 2 quarters · filed 2022-05-11 | $200.00K derived: sum of 3 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $100.00K derived: sum of 2 quarters · filed 2022-03-14 | $100.00K 10-K · filed 2022-03-14 | |||
| 2020-09-30 | $37.00K 10-Q · filed 2020-11-18 | $37.00K 10-Q · filed 2020-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |